We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
- Authors
Motonobu Saito; Kouya Shiraishi; Akiteru Goto; Hiroyuki Suzuki; Takashi Kohno; Koji Kono
- Abstract
Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC. Recent advances in the understanding of molecular biology have revealed several candidate therapeutic targets. To date, poly [ADP-ribose] polymerase (PARP), enhancer of zeste homologue 2 (EZH2) or delta-like canonical Notch ligand 3 (DLL3) are considered to be druggable targets in SCLC. In addition, another candidate of personalized therapy for SCLC is immune blockade therapy of programmed death-1 (PD-1) and its ligand, PD-L1. PD-1/ PD-L1 blockade therapy is not a standard therapy for SCLC, so many clinical trials have been performed to investigate its efficacy. Herein, we review gene aberrations exploring the utility of targeted therapy and discuss blockade of immune checkpoints therapy in SCLC.
- Publication
Japanese Journal of Clinical Oncology, 2018, Vol 48, Issue 7, p603
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyy068